Psychiatric Medications: What Just Arrived and What’s Coming Next(2023–2026)

For: Schizophrenia in adults

Why it matters: This is the single most important new psychopharm approval in this period. FDA explicitly called it the first antipsychotic for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Mechanism

Xanomeline stimulates central muscarinic M1/M4 receptors; trospium is added to reduce peripheral cholinergic effects.

Clinical use / action

Know the contraindications and GI/cholinergic profile; think about patients with psychosis who failed or could not tolerate dopamine-blocking antipsychotics, but do not oversell long-term real-world data yet.

Caveats

Short-term trials drove approval. Cost, payer restrictions, GI tolerability, anticholinergic balancing, and comparative effectiveness versus clozapine/LAIs remain open questions.

Hype check

REAL breakthrough mechanism — not just another D2 blocker.

Timing

Approved; real-world adoption underway

For: Schizophrenia in adults; acute manic or mixed episodes associated with bipolar I disorder

Why it matters: It is a new FDA novel drug and adds another approved antipsychotic/antimanic option, but it is not a new-mechanism event like Cobenfy.

Mechanism

Atypical antipsychotic; dopamine D2 and serotonin 5-HT2A antagonism. Milsaperidone is closely related to iloperidone/Fanapt and interconverts with it in vivo.

Clinical use / action

Treat as a cousin of iloperidone: watch QTc, orthostasis, CYP2D6/CYP3A interactions, titration burden, metabolic risks, and usual antipsychotic boxed warning issues.

Caveats

Marketing calls it a new chemical entity; clinically, it may not feel very different from Fanapt. Analysts have questioned differentiation.

Hype check

FDA-approved, but hype should be kept on a leash.

Timing

Approved; launch planned 2026

For: Postpartum depression in adults

Why it matters: First oral medication specifically approved for postpartum depression. It is not an SSRI and is intended as a short course rather than an indefinite daily antidepressant.

Mechanism

Neuroactive steroid; positive allosteric modulator of GABA-A receptors. Oral 14-day course.

Clinical use / action

Useful to know for severe PPD, urgent symptom burden, and patients who need something faster than standard SSRI timelines. Consider sedation/driving cautions and breastfeeding discussion.

Caveats

Not approved for general MDD. Duration of benefit, cost, access, lactation comfort, and how to sequence with psychotherapy/SSRIs matter.

Hype check

Genuinely different, but indication is narrow.

Timing

Approved

For: Major depressive disorder in adults

Why it matters: A non-SSRI/SNRI antidepressant option with a long and controversial development history. The key differentiation is 5-HT1A agonism and possible lower sexual side effect burden.

Mechanism

Selective serotonin 5-HT1A receptor agonist, once daily extended release.

Clinical use / action

Think of it as another antidepressant option when sexual dysfunction, weight, emotional blunting, or SSRI/SNRI intolerance are major concerns. Do not assume superior efficacy.

Caveats

The approval was based on limited trial evidence and the drug had a long regulatory saga. Availability, formulary position, and real-world uptake are practical issues.

Hype check

Interesting option — not a miracle antidepressant.

Timing

Approved

For: Treatment-resistant depression in adults

Why it matters: Big practical change: it can now be used as monotherapy for TRD, instead of requiring combination with an oral antidepressant.

Mechanism

NMDA/glutamate-pathway drug, clinic-administered under REMS.

Clinical use / action

Important for patients who cannot tolerate oral antidepressants or have inadequate response after multiple trials. Still requires in-clinic administration, monitoring, and REMS workflow.

Caveats

Not the same as home ketamine. FDA warns compounded ketamine is not approved for any psychiatric disorder. Cost and clinic workflow remain major barriers.

Hype check

Very clinically useful label flexibility.

Timing

Expanded label approved

For: Adjunctive treatment of MDD in adults

Why it matters: Adds a new adjunctive MDD option to its schizophrenia and bipolar depression uses. Trial reports emphasized efficacy with no mean weight/metabolic/sexual side-effect signal versus placebo in the trials.

Mechanism

Atypical antipsychotic with serotonin 5-HT2A antagonism, lower striatal D2 occupancy, serotonin reuptake effects, and glutamatergic modulation described in literature/label discussions.

Clinical use / action

Consider as an adjunctive MDD option where aripiprazole, brexpiprazole, quetiapine XR, lithium, T3, or esketamine are not good fits. Watch antipsychotic class warnings.

Caveats

Mechanism is not fully nailed down. Real-world metabolic/EPS experience, cost, and payer restrictions will decide its day-to-day value.

Hype check

Useful addition, especially if tolerability holds up.

Timing

Expanded label approved

For: Agitation associated with dementia due to Alzheimer’s disease

Why it matters: First FDA-approved non-antipsychotic drug for agitation associated with Alzheimer’s dementia. This matters because antipsychotics carry frightening risks in this population.

Mechanism

Dextromethorphan acts on NMDA/sigma-1 pathways; bupropion raises dextromethorphan exposure and contributes antidepressant pharmacology.

Clinical use / action

Not PRN. It is scheduled treatment. Watch seizure risk, drug interactions, blood pressure, CYP2D6 issues, serotonin syndrome risk, and caregiver expectations.

Caveats

Not for dementia psychosis per se; agitation trials support use, but frail older adult tolerability and polypharmacy need caution.

Hype check

Very important new option for a hard clinical problem.

Timing

Approved; launch for indication in 2026

For: Agitation associated with dementia due to Alzheimer’s disease

Why it matters: First FDA-approved medication for agitation associated with Alzheimer’s dementia. It slightly predates the requested window but belongs in the clinical landscape.

Mechanism

Serotonin-dopamine activity modulator; atypical antipsychotic class.

Clinical use / action

Useful when agitation is dangerous or severely impairing and non-drug approaches are inadequate. Discuss boxed warning, stroke, sedation, falls, and mortality concerns.

Caveats

Antipsychotic in dementia remains a high-risk decision, even with an FDA indication.

Hype check

Clinically important but risk-heavy.

Timing

Approved May 2023

For: Acute manic or mixed episodes associated with bipolar I disorder in adults

Why it matters: Existing schizophrenia drug gained bipolar mania/mixed labeling. It adds choice but not a novel mechanism.

Mechanism

Atypical antipsychotic; dopamine D2/serotonin 5-HT2A antagonist profile.

Clinical use / action

Think about QTc, orthostasis, titration, and whether faster antimanic options are needed. Not usually a first reflex in acute mania if speed is crucial.

Caveats

Differentiation versus many generic antipsychotics may be limited.

Hype check

Useful label expansion, not a revolution.

Timing

Expanded label approved

For: Maintenance treatment of bipolar I disorder in adults

Why it matters: A practical adherence tool. It expands a schizophrenia LAI into bipolar I maintenance, with monthly dosing for the bipolar indication.

Mechanism

Long-acting subcutaneous risperidone formulation.

Clinical use / action

Relevant for relapse-prone bipolar I patients with nonadherence. Discuss prolactin, EPS, metabolic issues, injection-site reactions, and oral overlap/labelling details.

Caveats

Not a new molecule. Value is formulation and adherence.

Hype check

Practical, not flashy — but practical often wins.

Timing

Expanded label approved

For: ADHD in children age 6+

Why it matters: First liquid extended-release nonstimulant ADHD medication in the U.S., and labeled with nighttime dosing.

Mechanism

Alpha-2 adrenergic agonist; extended-release liquid suspension.

Clinical use / action

Helpful for children who cannot swallow pills, have tics/insomnia/aggression, or need nonstimulant adjunctive treatment. Watch sedation, hypotension, bradycardia, rebound hypertension if stopped abruptly.

Caveats

Mechanism is old; formulation is the innovation.

Hype check

Small but very practical pediatric win.

Timing

Approved

For: Moderate-to-severe opioid use disorder

Why it matters: Important addiction psychiatry option because weekly dosing can bridge induction/stabilization and monthly dosing can support adherence.

Mechanism

Weekly and monthly subcutaneous buprenorphine depot.

Clinical use / action

Consider for patients already on or starting transmucosal buprenorphine who need depot treatment. Behavioral therapy and counseling remain part of care.

Caveats

OUD treatment logistics, pharmacy access, prior authorization, precipitated withdrawal risk, and patient preference matter.

Hype check

Highly useful formulation advance.

Timing

Approved May 2023

For: Known or suspected opioid overdose

Why it matters: First nalmefene nasal spray for overdose reversal in health care/community settings.

Mechanism

Opioid receptor antagonist; longer-acting nalmefene nasal spray.

Clinical use / action

Know it exists, but do not casually replace naloxone in all settings. Nalmefene may produce longer withdrawal in opioid-dependent patients.

Caveats

Some toxicology groups have cautioned nalmefene should not replace naloxone as primary antidote without more field data.

Hype check

Useful tool, but not automatically better than naloxone.

Timing

Approved

For: Known or suspected opioid overdose, age 12+

Why it matters: First nalmefene auto-injector. Device format may matter for community and emergency use.

Mechanism

Opioid receptor antagonist in auto-injector format.

Clinical use / action

Worth knowing for harm-reduction discussions, emergency kits, and high-fentanyl-risk settings.

Caveats

Same nalmefene caveat: longer antagonist effect can mean longer withdrawal; naloxone remains the familiar standard in many protocols.

Hype check

Device innovation, not a psychiatric maintenance drug.

Timing

Approved

For: Emergency treatment of known or suspected opioid overdose

Why it matters: Not a psychiatric medication in the narrow sense, but profoundly relevant to addiction psychiatry and community harm reduction.

Mechanism

Opioid receptor antagonist available without prescription in several nasal spray products.

Clinical use / action

Encourage patients/families at opioid risk to keep it available and know how to use it. Explain rescue breathing/EMS and repeat dosing.

Caveats

Access, cost, stigma, and education are the limiting factors.

Hype check

Public-health blockbuster.

Timing

OTC access expanded

For: Narcolepsy cataplexy or excessive daytime sleepiness

Why it matters: Sleep medicine overlap: once-nightly dosing reduces the middle-of-the-night second dose burden seen with older oxybate products.

Mechanism

Once-nightly extended-release sodium oxybate; CNS depressant under restricted program.

Clinical use / action

Relevant when evaluating narcolepsy, severe hypersomnia, cataplexy, and complex sleep complaints that look psychiatric.

Caveats

Abuse/misuse, respiratory depression, CNS depressant interactions, depression/suicidality warnings, sodium burden, REMS-like restrictions.

Hype check

Formulation matters; not core psychiatry but clinically relevant.

Timing

Approved/expanded

For: Treatment-resistant schizophrenia; suicide risk in schizophrenia/schizoaffective disorder

Why it matters: This may be one of the most important real-world schizophrenia changes because administrative friction has historically blocked clozapine access.

Mechanism

Not a new medication. Practice-change: the FDA eliminated the REMS program burden while ANC (absolute neutrophil count) monitoring remains clinically important.

Clinical use / action

Do not stop ANC monitoring just because REMS is gone — it is still recommended. Use the change to reduce barriers for appropriate treatment-resistant schizophrenia patients.

Caveats

Operational changes may take time across pharmacies, EHRs, and clinics.

Hype check

Huge access implication for an old gold-standard drug.

Timing

REMS eliminated effective June 13, 2025 (FDA stopped requiring REMS participation Feb. 24, 2025)

For: ADHD age 6+; moderate-to-severe binge-eating disorder in adults

Why it matters: Probably the biggest psychiatric generic event of the period. It should reduce cost, but real-world shortages have complicated the benefit.

Mechanism

Prodrug amphetamine stimulant; Schedule II.

Clinical use / action

Ask pharmacy which manufacturer is available; consider formulation equivalence, supply instability, prior authorizations, and patient-reported response differences.

Caveats

FDA approval does not guarantee easy availability. Controlled-substance quotas and shortages remain common.

Hype check

Big cost/access change, uneven in reality.

Timing

Generic approved 2023; shortages variable

For: Schizophrenia; bipolar depression

Why it matters: Very important practical win: lurasidone moved from expensive branded drug to a much more usable bipolar depression/schizophrenia option.

Mechanism

Atypical antipsychotic; D2/5-HT2A profile with bipolar depression labeling.

Clinical use / action

Useful for bipolar depression when weight/metabolic risk, sedation, and cost shape choices. Remember food requirement and akathisia risk.

Caveats

FDA first generic approval dates were earlier than market availability. The clinical event was 2023 availability/cost shift, not a first-approval event.

Hype check

Cost drop makes an old tool newly useful.

Timing

Available generically since 2023

For: Hallucinations and delusions associated with Parkinson’s disease psychosis

Why it matters: A potential neuropsychiatry cost/access event — but only on paper so far. Pimavanserin is unique because it treats Parkinson’s disease psychosis without D2 blockade worsening motor symptoms.

Mechanism

Selective serotonin 5-HT2A inverse agonist/antagonist; non-dopaminergic antipsychotic approach.

Clinical use / action

Useful in Parkinson’s psychosis, but boxed warning and QT issues still matter.

Caveats

Critically, although the FDA approved a first generic (ANDA) on Jan. 16, 2024, no generic pimavanserin is actually marketed in the U.S. as of 2026 — so the cost/access benefit remains theoretical. It is also not approved for general schizophrenia, dementia psychosis unrelated to PDP, or negative symptoms of schizophrenia.

Hype check

Approved on paper — no marketed generic yet.

Timing

First generic (ANDA) approved 2024; no marketed generic as of 2026

For: Schizophrenia in adults; brand also used in bipolar I maintenance labeling contexts

Why it matters: Potentially important because LAIs are often blocked by cost. Generic aripiprazole ER injection may improve access.

Mechanism

D2 partial agonist LAI.

Clinical use / action

Useful for schizophrenia patients where adherence is the main relapse driver. Check exact generic label/coverage and do not assume all brand indications transfer identically.

Caveats

FDA first-generic approval does not equal marketed availability — treat the access improvement as pending until a generic is actually on pharmacy shelves. Formulary adoption can lag. Injection logistics still matter.

Hype check

Potentially big access improvement — once it is actually on shelves.

Timing

First generic approved 2024; marketed availability pending

For: Mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation

Why it matters: Can help manage opioid withdrawal symptoms without being an opioid agonist.

Mechanism

Central alpha-2 adrenergic agonist; reduces autonomic withdrawal symptoms.

Clinical use / action

Use as withdrawal-symptom support, not as OUD maintenance treatment. Watch hypotension, bradycardia, QT risk, sedation, and cost.

Caveats

Does not treat OUD long-term and does not prevent cravings/relapse like buprenorphine or methadone.

Hype check

Useful but narrow.

Timing

First generic 2024

For: FDA first-generic table lists Huntington’s disease chorea indication

Why it matters: A footnote-level item. It is listed in FDA first-generic tables, with potential neuropsychiatry relevance because VMAT2 inhibitors overlap with movement-disorder side effects seen in psychiatric practice.

Mechanism

VMAT2 inhibitor.

Clinical use / action

Be careful: FDA first-generic table language found for this approval emphasized Huntington’s chorea; do not assume broad TD substitution without checking current label/formulary.

Caveats

Listed in FDA first-generic tables; a marketed generic’s availability is unconfirmed as of 2026, so this should not be presented as a realized access change. Depression/suicidality warnings in Huntington’s disease and parkinsonism/akathisia risks matter.

Hype check

Footnote only — not a realized access change.

Timing

First-generic table entry 2024; marketed availability unconfirmed as of 2026

For: MDD in adults; sertraline itself long generic in tablets/liquid

Why it matters: This is only a formulation-specific generic event, not a new generic for sertraline overall.

Mechanism

SSRI.

Clinical use / action

Mostly a pharmacy/formulation footnote. It does not change the SSRI landscape.

Caveats

Do not confuse formulation-specific first generic with the original drug becoming generic decades ago.

Hype check

Tiny practical relevance.

Timing

First-generic table entry 2025

For: Anesthesia indication, not psychiatric indication

Why it matters: Important only because patients see ketamine everywhere and assume FDA psych approval. FDA has specifically warned that compounded ketamine products are not FDA-approved for psychiatric disorders.

Mechanism

NMDA receptor antagonist; anesthetic.

Clinical use / action

Use this to explain the difference between FDA-approved esketamine for TRD and off-label/compounded ketamine.

Caveats

A generic anesthetic approval is not approval for depression, anxiety, PTSD, OCD, or home use.

Hype check

Useful teaching point, not a psychiatric approval.

Timing

First-generic table entry 2025

For: ADHD in children, adolescents, and adults

Why it matters: Closest near-term pipeline event. FDA PDUFA target action date is July 24, 2026.

Mechanism

First-in-class norepinephrine/dopamine/serotonin reuptake inhibitor (NDSRI).

Clinical use / action

If approved, it may sit between classic stimulants and current nonstimulants. Watch appetite, sleep, BP/HR, mood activation, and controlled-substance status in final label.

Caveats

Not approved yet. Need final label, abuse-liability language, and comparative data versus stimulants/atomoxetine/viloxazine.

Hype check

Highest near-term ADHD watch.

Timing

PDUFA July 24, 2026

For: Treatment-resistant depression

Why it matters: Potentially the most workflow-changing depression treatment if approved: not daily pills, but structured psychedelic sessions with support and monitoring.

Mechanism

Classic serotonergic psychedelic given in a supervised psychological-support model.

Clinical use / action

Prepare for questions about eligibility, psychosis/bipolar exclusion, suicidality, cardiovascular screening, therapist/training models, REMS-like controls, and cost.

Caveats

Company-reported data are promising, but final FDA review, label, safety controls, durability, and implementation are not settled.

Hype check

Possibly transformative — but operationally complicated.

Timing

Possible 2026–2027; no firm PDUFA found

For: Major depressive disorder

Why it matters: Broader indication than COMP360’s TRD focus; if successful, it could move psychedelic treatment beyond narrow TRD populations.

Mechanism

Synthetic psilocybin in a controlled therapeutic setting.

Clinical use / action

Not prescribable. Watch trial design, blinding, therapist model, adverse-event reporting, and how FDA handles psychotherapy components.

Caveats

Earlier/less mature public regulatory pathway than COMP360 based on what could be verified.

Hype check

Exciting but less near-term than COMP360.

Timing

No firm approval date

For: PTSD

Why it matters: Could become the next PTSD psychedelic/entactogen program after MDMA’s regulatory setback.

Mechanism

Entactogen/empathogen-like compound related conceptually to MDMA but chemically distinct.

Clinical use / action

Watch trial integrity, blinding, therapist conduct, cardiovascular monitoring, abuse liability, and durability of response.

Caveats

Less mature than COMP360. MDMA’s rejection shows FDA will scrutinize psychedelic-assisted therapy hard.

Hype check

Interesting, but not close enough to plan around clinically.

Timing

No firm approval date

For: Generalized anxiety disorder

Why it matters: Anxiety drug development has been sleepy for years. A psychedelic-class GAD candidate is genuinely different if Phase 3 confirms benefit.

Mechanism

Single-dose or intermittent psychedelic serotonergic mechanism, not daily SSRI/SNRI/benzodiazepine treatment.

Clinical use / action

Watch mania/psychosis exclusions, acute perceptual effects, driving/work restrictions, psychotherapy/support requirements, and durability.

Caveats

Not approved. Breakthrough Therapy designation speeds development but does not prove efficacy or safety.

Hype check

High-interest anxiety pipeline.

Timing

No firm approval date

For: MDD with insomnia symptoms; insomnia disorder studies

Why it matters: Different because it targets sleep-wake biology in depressed patients with insomnia rather than directly pushing serotonin/norepinephrine/dopamine.

Mechanism

Selective orexin-2 receptor antagonist.

Clinical use / action

Could be useful where residual insomnia perpetuates depression and clinicians reach for sedating antipsychotics. Watch comparison with quetiapine XR and insomnia outcomes.

Caveats

No FDA approval date. Program has positive data but psychiatric pipelines often look good until the final trial package is judged.

Hype check

Very interesting if label is clean.

Timing

No firm approval date

For: Schizophrenia in adults

Why it matters: Olanzapine works, but adherence and existing LAI monitoring burdens limit use. A monthly subcutaneous product could matter if safety/monitoring is favorable.

Mechanism

Once-monthly subcutaneous long-acting olanzapine formulation.

Clinical use / action

If approved, learn whether it avoids or changes post-injection delirium/sedation monitoring requirements. Metabolic risk remains olanzapine risk.

Caveats

Not approved yet. Final label will decide whether this is clinically liberating or administratively similar to older olanzapine LAI concerns.

Hype check

Potentially practical for a powerful old drug.

Timing

NDA accepted; possible 2026 review

For: Schizophrenia

Why it matters: Potentially interesting for negative symptoms/cognition/tolerability claims, but it needs another Phase 3 before approval can be realistic.

Mechanism

Serotonin-dopamine signaling modulator; company describes activity across serotonin/dopamine targets and anti-inflammatory hypotheses.

Clinical use / action

Watch RECOVER-2 design, dropout, metabolic/EPS data, QT/prolactin, and whether negative-symptom claims survive rigorous testing.

Caveats

No near-term approval without additional successful trial.

Hype check

Worth watching, not ready.

Timing

Second Phase 3 planned/needed

For: Social anxiety disorder; PTSD programs

Why it matters: Interesting because it aims for acute/as-needed anxiolysis without benzodiazepine sedation/addiction liabilities.

Mechanism

Negative allosteric modulator of alpha-7 nicotinic acetylcholine receptor.

Clinical use / action

If successful, it could fill a big gap: performance/social anxiety episodes where propranolol/benzos/SSRIs are imperfect.

Caveats

Not approved. Social anxiety trials have been placebo-sensitive, and competitors have recently failed.

Hype check

Promising concept, high trial-risk.

Timing

Phase 3; no firm approval date

For: Suicidal bipolar depression / suicidal ideation in depression

Why it matters: Clinically interesting because suicidal bipolar depression is a high-risk, under-served niche where fast-acting options are limited.

Mechanism

NMDA-modulating strategy combined with lurasidone; related sequence after ketamine stabilization.

Clinical use / action

Do not treat as available. Watch whether the final program is NDA/ANDA hybrid, what indication is actually accepted, and how ketamine sequencing is handled.

Caveats

Company announcements are not FDA approval. Evidence package and path are complex.

Hype check

Interesting niche but still uncertain.

Timing

No firm approval date

For: PTSD

Why it matters: This is the cautionary tale for the whole psychedelic field: strong-looking efficacy is not enough if trial conduct, blinding, safety documentation, or therapy model raises FDA concerns.

Mechanism

Entactogen plus psychotherapy model.

Clinical use / action

Patients will ask. Be honest: not FDA-approved; further data requested.

Caveats

Do not refer patients expecting imminent legal MDMA treatment outside clinical trials.

Hype check

Major setback, but not the end of the field.

Timing

Not approved; another trial requested

For: Schizophrenia

Why it matters: Once very exciting because it was non-D2. Two Phase 3 failures made approval uncertain.

Mechanism

TAAR1 agonist / 5-HT1A agonist, non-D2 approach.

Clinical use / action

Do not count it as near-term. Still scientifically interesting, but no longer a dependable pipeline hope.

Caveats

Phase 3 placebo response and psychiatric trial fragility are the story.

Hype check

Cool mechanism, bad late-stage outcome.

Timing

Uncertain after failed Phase 3

For: Schizophrenia

Why it matters: This matters because it was supposed to be a Cobenfy competitor in the muscarinic lane. Failure strengthened Cobenfy’s position.

Mechanism

Muscarinic M4 positive allosteric modulator.

Clinical use / action

Shows muscarinic does not automatically mean successful. Details of receptor subtype, agonist/PAM, dose, and trial design matter.

Caveats

Not a near-term approved option.

Hype check

Big disappointment.

Timing

Program uncertain after failure

For: Major depressive disorder/anhedonia

Why it matters: This is a major warning about the kappa-antagonist/anhedonia depression thesis. It repeatedly failed late-stage trials.

Mechanism

Kappa opioid receptor antagonist.

Clinical use / action

Do not expect imminent KOR-antagonist depression prescribing from this program.

Caveats

The class may not be dead, but this lead program is effectively dead for MDD.

Hype check

Hype collapsed.

Timing

Discontinued

For: MDD with anhedonia adjunctive treatment

Why it matters: Another blow to kappa-antagonist depression development.

Mechanism

Kappa opioid receptor antagonist.

Clinical use / action

Do not keep it on a near-term MDD watch list.

Caveats

May be explored elsewhere, but not a viable imminent MDD drug.

Hype check

Important negative result.

Timing

MDD program stopped

For: Social anxiety disorder

Why it matters: Shows the social-anxiety/as-needed anxiolytic field is risky and placebo-sensitive.

Mechanism

Intranasal pherine/neuroactive nasal spray concept for acute anxiety.

Clinical use / action

Not approved. Useful to contrast with BNC210 and MM120 as still-uncertain anxiety programs.

Caveats

One failed Phase 3 does not always end a program, but it sharply lowers confidence.

Hype check

Neat concept, weak latest result.

Timing

Phase 3 miss